alisporivir
Small moleculeexperimental
Alisporivir (INN), or Debio 025, DEB025, is a cyclophilin inhibitor. Its structure is reminiscent of, and synthesized from ciclosporin. — Wikipedia
Clinical trial activity
15 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
10
Phase 3
5
Phase 4
0
Earliest trial started Sep 1, 2007 (NCT00537407)
Timeline
Indications
Mechanism of action
- Cyclophilin AINHIBITOR
PPIA inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)[C@H](C)C(=O)N(CC)[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C- Mol. weight
- 1216.66 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaAlisporivir ↗
- ChEMBLCHEMBL1651956 ↗
Also known as
- alisporivir
- alisporivir
- alisporivir
- alisporivir
- alisporivir
- deb025
- deb025
- deb025
- debio 025
- debio 025
- debio 025
- debio-025
- meala(3)etval(4)-cyclosporin
- unil025
- unil 025
- unil-025
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04608214 | Phase 2 | Nov 1, 2020 | Assistance Publique - Hôpitaux de Paris, Debiopharm, University of Paris |
| NCT02173574 | Phase 1 | Aug 1, 2014 | Enanta Pharmaceuticals |
| NCT02094443 | Phase 2 | Mar 1, 2014 | Debiopharm, Novartis |
| NCT01970904 | N/A | Oct 1, 2013 | Debiopharm, Novartis |
| NCT01975337 | Phase 1 | Aug 1, 2013 | Debiopharm, Novartis |
| NCT02465203 | Phase 3 | Sep 1, 2012 | Novartis |
| NCT01500772 | Phase 3 | Mar 1, 2012 | Debiopharm, Novartis |
| NCT01446250 | Phase 3 | Dec 1, 2011 | Debiopharm, Novartis |
| NCT02753699 | Phase 3 | Dec 1, 2011 | Debiopharm, Novartis |
| NCT01860326 | Phase 1 | Mar 1, 2011 | Debiopharm, Novartis |
| NCT01318694 | Phase 3 | Mar 1, 2011 | Debiopharm, Novartis |
| NCT01215643 | Phase 2 | Oct 1, 2010 | Debiopharm, Novartis |
| NCT01183169 | Phase 2 | Aug 1, 2010 | Debiopharm, Novartis |
| NCT00854802 | N/A | Jan 1, 2009 | Debiopharm, Parexel |
| NCT00537407 | Phase 2 | Sep 1, 2007 | Debiopharm |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Debiopharm | For profit | 13 | 12 | 4 | 2007 |
| Novartis | For profit | 11 | 1 | 4 | 2010 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Enanta Pharmaceuticals | For profit | 1 | 1 | 1 | 2014 |
| Parexel | For profit | 1 | 0 | 1 | 2009 |
| University of Paris | Academic/Hospital | 1 | 0 | 1 | 2020 |
6 organizations
Page 1 / 1